We are pleased to announce our collaboration with Institute of Science Tokyo , the Graduate School of The University of Tokyo, and the Graduate School of Kobe University on the FY2025 “Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis (Drug Development Using Next-generation Drug-Delivery System),” which has been selected by the Japan Agency for Medical Research and Development (AMED).
Specifically, we will contribute to the clinical advancement of these innovative oligonucleotide therapeutics by providing (synthesizing) the active-targeting ligands that are key to this technology, manufacturing the active pharmaceutical ingredient (API) for Good Laboratory Practice (GLP) studies of the development candidate, establishing a supply system, and conducting studies to confirm their potential.
For more details, please see below.
20260218_AMED FY2025_AMED-Funded Research News Release（Rena Therapeutics）